Du är här

2016-02-15

DBV Technologies: DBV Technologies Reports December 31, 2015, Cash Position

-----------------------------------------
| Press Release |
| |
|Montrouge, France, February 15th, 2016 |
-----------------------------------------

DBV Technologies Reports

December 31, 2015, Cash Position

DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
its cash and cash equivalents as of December 31, 2015. DBV's 2015 full-year
results are scheduled to be released on April 7, 2016.

Cash and cash equivalents

DBV's cash and cash equivalents amounted to €324.0 million as of December 31,
2015, compared to €332.2 million as of September 30, 2015.

Number of outstanding shares

As of December 31, 2015, DBV's number of outstanding shares was 24,205,129
ordinary shares, compared to 19,160,661 ordinary shares outstanding as of
December 31, 2014.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing
in prevalence. DBV Technologies, incorporated in France in 2002, has
developed a proprietary, patented technology for administering an allergen to
intact skin while avoiding transfer to the blood, and thus lowering the risk
of a systemic, allergic reaction in the event of accidental exposure. DBV
Technologies is focusing on food allergies, including milk and peanut, for
which there are currently no effective treatments. DBV Technologies has
designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The
clinical development program for Viaskin® Peanut has received Fast Track
designation and Breakthrough Therapy designation from the U.S. Food and Drug
Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of
American Depositary Shares (each representing one-half of one ordinary share)
(Ticker: DBVT). For more information on DBV Technologies, please visit our
website:www.dbv-technologies.com

Forward Looking Statements

This press release contains forward-looking statements forward-looking
statements that are not promises or guarantees and involve substantial risks
and uncertainties. The Company's product candidates have not been approved
for sale in any jurisdiction. Among the factors that could cause actual
results to differ materially from those described or projected herein are
uncertainties associated generally with research and development, clinical
trials and related regulatory reviews and approvals, the risk that historical
preclinical results may not be predictive of future clinical trial results,
and the risk that historical clinical trial results may not be predictive of
future trial results. A further list and description of these risks,
uncertainties and other risks can be found in the Company's regulatory
filings with the French Autorité des Marchés Financiers, the Company's
Securities and Exchange Commission filings and reports, including in the
Company's Annual Report on Form 20-F for the year ended December 31, 2014 and
future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. DBV Technologies
undertakes no obligation to update or revise the information contained in
this Press Release, whether as a result of new information, future events or
circumstances or otherwise.

----------------------------------------------------------------------------------------------------
| DBV Technologies Contacts |
| Nathalie Donne Susanna Mesa |
| |
| VP Finance, US Investor Relations&Strategy |
|Director, Corporate Communication&Business Development Tél. : +1 917-346-3447 |
| susanna.mesa@dbv-technologies.com |
|Tél. : +33(0)1 55 42 78 72 |
|nathalie.donne@dbv-technologies.com |
| DBV Technologies Media Contacts US&Europe |
| Marion Janic Caroline Carmagnol |
| |
| |
|Rooney&Associates Alize RP - Relation Presse |
| |
|Tél. : +1-212-223-4017 Tél. : +33(0)6 64 18 99 59 |
|mjanic@rooneyco.com |
| caroline@alizerp.com |
----------------------------------------------------------------------------------------------------
PDF Version
http://hugin.info/156437/R/1985998/728511.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

HUG#1985998

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.